Cargando…

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

BACKGROUND: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. METHODS: Among pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Wonjun, Choi, Chang-Min, Rho, Jin Kyung, Jang, Se Jin, Park, Young Soo, Chun, Sung-Min, Kim, Woo Sung, Lee, Jung-Shin, Kim, Sang-We, Lee, Dae Ho, Lee, Jae Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877961/
https://www.ncbi.nlm.nih.gov/pubmed/24369725
http://dx.doi.org/10.1186/1471-2407-13-606
_version_ 1782297724789456896
author Ji, Wonjun
Choi, Chang-Min
Rho, Jin Kyung
Jang, Se Jin
Park, Young Soo
Chun, Sung-Min
Kim, Woo Sung
Lee, Jung-Shin
Kim, Sang-We
Lee, Dae Ho
Lee, Jae Cheol
author_facet Ji, Wonjun
Choi, Chang-Min
Rho, Jin Kyung
Jang, Se Jin
Park, Young Soo
Chun, Sung-Min
Kim, Woo Sung
Lee, Jung-Shin
Kim, Sang-We
Lee, Dae Ho
Lee, Jae Cheol
author_sort Ji, Wonjun
collection PubMed
description BACKGROUND: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. METHODS: Among patients at a tertiary referral hospital in Korea who initially responded well to gefitinib and later acquired resistance to treatment, we selected those with enough tissues obtained before EGFR-TKI treatment and after the onset of resistance to examine mutations by mass spectrometric genotyping technology (Asan-Panel), MET amplification by fluorescence in situ hybridization (FISH), and analysis of AXL status, epithelial-to-mesenchymal transition (EMT) and neuroendocrine markers by immunohistochemistry. RESULTS: Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del). Secondary T790M mutation was detected in 11 subjects (42.3%) and four of these patients had other co-existing resistance mechanisms; increased AXL expression was observed in 5/26 patients (19.2%), MET gene amplification was noted in 3/26 (11.5%), and one patient acquired a mutation in the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) gene. None of the patients exhibited EMT; however, increased CD56 expression suggesting neuroendocrine differentiation was observed in two patients. Interestingly, conversion from L858R-mutant to wild-type EGFR occurred in one patient. Seven patients (26.9%) did not exhibit any known resistance mechanisms. Patients with a T790M mutation showed a more favorable prognosis. CONCLUSION: The mechanisms and frequency of acquired EGFR-TKI resistance in Koreans are comparable to those observed in Western populations; however, more data regarding the mechanisms that drive EGFR-TKI resistance are necessary.
format Online
Article
Text
id pubmed-3877961
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38779612014-01-03 Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer Ji, Wonjun Choi, Chang-Min Rho, Jin Kyung Jang, Se Jin Park, Young Soo Chun, Sung-Min Kim, Woo Sung Lee, Jung-Shin Kim, Sang-We Lee, Dae Ho Lee, Jae Cheol BMC Cancer Research Article BACKGROUND: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. METHODS: Among patients at a tertiary referral hospital in Korea who initially responded well to gefitinib and later acquired resistance to treatment, we selected those with enough tissues obtained before EGFR-TKI treatment and after the onset of resistance to examine mutations by mass spectrometric genotyping technology (Asan-Panel), MET amplification by fluorescence in situ hybridization (FISH), and analysis of AXL status, epithelial-to-mesenchymal transition (EMT) and neuroendocrine markers by immunohistochemistry. RESULTS: Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del). Secondary T790M mutation was detected in 11 subjects (42.3%) and four of these patients had other co-existing resistance mechanisms; increased AXL expression was observed in 5/26 patients (19.2%), MET gene amplification was noted in 3/26 (11.5%), and one patient acquired a mutation in the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) gene. None of the patients exhibited EMT; however, increased CD56 expression suggesting neuroendocrine differentiation was observed in two patients. Interestingly, conversion from L858R-mutant to wild-type EGFR occurred in one patient. Seven patients (26.9%) did not exhibit any known resistance mechanisms. Patients with a T790M mutation showed a more favorable prognosis. CONCLUSION: The mechanisms and frequency of acquired EGFR-TKI resistance in Koreans are comparable to those observed in Western populations; however, more data regarding the mechanisms that drive EGFR-TKI resistance are necessary. BioMed Central 2013-12-27 /pmc/articles/PMC3877961/ /pubmed/24369725 http://dx.doi.org/10.1186/1471-2407-13-606 Text en Copyright © 2013 Ji et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ji, Wonjun
Choi, Chang-Min
Rho, Jin Kyung
Jang, Se Jin
Park, Young Soo
Chun, Sung-Min
Kim, Woo Sung
Lee, Jung-Shin
Kim, Sang-We
Lee, Dae Ho
Lee, Jae Cheol
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
title Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
title_full Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
title_fullStr Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
title_full_unstemmed Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
title_short Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
title_sort mechanisms of acquired resistance to egfr-tyrosine kinase inhibitor in korean patients with lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877961/
https://www.ncbi.nlm.nih.gov/pubmed/24369725
http://dx.doi.org/10.1186/1471-2407-13-606
work_keys_str_mv AT jiwonjun mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT choichangmin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT rhojinkyung mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT jangsejin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT parkyoungsoo mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT chunsungmin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT kimwoosung mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT leejungshin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT kimsangwe mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT leedaeho mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer
AT leejaecheol mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer